A key clinical breakthrough was announced at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. TYK MEDICINES-B (02410), a Hong Kong-listed innovative pharmaceutical company, presented interim analysis results from the pivotal Phase II ESAONA study for its self-developed, next-generation EGFR-TKI innovative drug, Edotinib Mesylate Tablets (TY-9591), in the frontline treatment of EGFR-mutant non-small cell lung cancer (NSCLC) patients with brain metastases. The results were released as a late-breaking abstract (LBA) oral presentation.
The study, led by Professor Shi Yuankai from the Cancer Hospital of the Chinese Academy of Medical Sciences, has garnered significant attention from global oncology experts, industry, and capital markets due to its groundbreaking intracranial efficacy data, marking a major advancement for domestic innovative drugs in the precise treatment of lung cancer brain metastases.
Addressing an Unmet Need: Edotinib's Strategic Focus on Lung Cancer Brain Metastases EGFR mutation is the most common driver mutation in NSCLC, and brain metastasis is the most severe form of metastasis in advanced lung cancer. It significantly shortens patient survival and severely impairs quality of life, representing a core clinical challenge and an unmet medical need. While current mainstream third-generation EGFR-TKI drugs can significantly improve overall survival for EGFR-mutant lung cancer patients, their ability to penetrate and inhibit brain metastases remains limited, resulting in suboptimal intracranial efficacy. There is a pressing clinical need for next-generation treatments with superior efficacy and safety.
Edotinib Mesylate Tablets are a highly selective, next-generation irreversible EGFR-TKI independently developed by TYK MEDICINES-B. As a differentiated deuterated innovation based on osimertinib, it leverages unique pharmacokinetic advantages to significantly reduce the generation of toxic metabolites. Early clinical studies have already demonstrated excellent intracranial lesion suppression and a favorable safety and tolerability profile, offering new potential for treating lung cancer brain metastases.
Head-to-Head Pivotal Phase II Study: Robust Design Ensures Data Authority The announced ESAONA study is an open-label, multicenter, randomized controlled pivotal Phase II clinical trial. It directly compares Edotinib against the global frontline standard therapy, osimertinib, to comprehensively validate the efficacy and safety of Edotinib as a first-line treatment for EGFR classic-mutant NSCLC patients with brain metastases. The study enrolled 224 patients, randomized 1:1 into the Edotinib group (160mg once daily) and the osimertinib group (80mg once daily). Stratification based on EGFR mutation subtype and number of intracranial lesions ensured balanced baseline characteristics between the groups.
The study's primary endpoints were intracranial objective response rate (iORR) and intracranial progression-free survival (iPFS), both assessed by blinded independent central review (BICR). It employed a multi-faceted approach to comprehensively evaluate intracranial efficacy, systemic anti-tumor efficacy, and safety. The rigorous study design ensures high data reliability and substantial clinical reference value.
Core Data Demonstrates Comprehensive Superiority, Setting New Efficacy Benchmarks As of December 15, 2025, with a median follow-up of 19.12 months, interim analysis data shows Edotinib outperforms osimertinib in both intracranial efficacy and systemic anti-tumor efficacy. This benefit advantage was consistent across all patient subgroups, demonstrating best-in-class potential.
1. Intracranial Efficacy Leads Significantly, with 95.5% iORR Delivering Breakthrough Benefit Controlling intracranial lesions is the primary goal in treating lung cancer brain metastases. This study's data sets a new record for EGFR-TKI intracranial efficacy. Under authoritative BICR assessment, the iORR in the Edotinib group reached 95.5%, significantly higher than the 79.6% in the osimertinib group. The between-group difference of 15.62% was statistically highly significant (P=0.0004). All pre-specified subgroup patients derived significant benefit from Edotinib treatment.
Intracranial survival benefit was equally impressive. The median iPFS for the Edotinib group was not yet reached, compared to 17.51 months for the osimertinib group (Hazard Ratio [HR]=0.46, P=0.0020). Long-term follow-up data shows the 18-month and 24-month iPFS rates for the Edotinib group were 75.24% and 61.56%, respectively, representing substantial improvement over the osimertinib group and effectively reducing the risk of intracranial disease progression.
Furthermore, the median intracranial duration of response (iDoR) for the Edotinib group was not yet reached, significantly better than the 16.26 months for the osimertinib group (HR=0.50, P=0.0148), offering patients more durable intracranial response. Additionally, investigator-assessed iORR and iPFS data based on both RECIST v1.1 and RANO-BM criteria were highly consistent with BICR results, further validating the stability and reliability of Edotinib's intracranial efficacy.
2. Clear Systemic Efficacy Advantage, Comprehensive Upgrade in Anti-Tumor Strength In terms of systemic anti-tumor efficacy, Edotinib also demonstrated significant clinical advantages. BICR assessment results showed the overall objective response rate (ORR) in the Edotinib group was 89.2%, higher than the 77.9% in the osimertinib group (P=0.0301). The median progression-free survival (PFS) was not yet reached for the Edotinib group, superior to the 17.22 months for the osimertinib group (HR=0.64, P=0.0473), effectively delaying systemic tumor progression and offering patients a longer period of survival benefit. Overall survival (OS) data is not yet mature, with ongoing follow-up expected to reveal more favorable long-term survival data.
Favorable Safety Profile with Manageable Tolerability, Combining Efficacy and Safety Safety is a core requirement for the clinical adoption and long-term use of innovative drugs. Safety data from this study shows Edotinib's overall safety profile is manageable. Adverse events were mostly mild to moderate and could be effectively managed with symptomatic treatment or dose adjustment. The incidence of treatment-emergent adverse events was comparable between the two groups. While the incidence of Grade ≥3 adverse events in the Edotinib group was 49.5%, higher than the control group, severe adverse reactions were effectively manageable. Both groups had 4 patients who permanently discontinued treatment due to treatment-related adverse events, fully demonstrating Edotinib's good clinical tolerability, supporting long-term standardized treatment and meeting clinical needs for prolonged therapy.
Commercialization Accelerates, Poised to Reshape Treatment Landscape Supported by the breakthrough positive data from the ESAONA study, Edotinib has demonstrated core product strengths of superior efficacy, manageable safety, and significant differentiated advantages. It is poised to become a new, preferred first-line option for EGFR-mutant lung cancer patients with brain metastases. Currently, the New Drug Application (NDA) for Edotinib Mesylate Tablets has been accepted by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration and included in the priority review and approval process, accelerating its path to market. If approved, it will rapidly address the upgraded need for precise treatment of lung cancer brain metastases in China, offering a new treatment choice for a broad population of advanced lung cancer patients.
Moving forward, TYK MEDICINES-B will continue to advance multiple clinical studies for Edotinib, both as monotherapy and in combination regimens, to continuously enrich the product's clinical evidence base. More clinical data will be disclosed subsequently. The company remains focused on unmet clinical needs in oncology, deepening its research and development in innovative kinase inhibitors, aiming to benefit global patients with high-quality domestic innovative drugs and continuously unlock its innovation value and growth potential in the capital market.
[About Edotinib Mesylate Tablets (TY-9591)] Edotinib Mesylate Tablets are a next-generation, highly selective, irreversible oral EGFR-TKI independently developed by TYK MEDICINES-B. It is a differentiated deuterated innovation based on osimertinib. Through unique structural optimization, the drug effectively reduces the generation of toxic metabolites and possesses superior pharmacokinetic characteristics, demonstrating outstanding clinical efficacy and safety advantages in populations with lung cancer brain metastases and EGFR L858R sensitive mutations. The company has initiated multiple monotherapy and combination therapy clinical studies for this product, comprehensively covering various subtypes of advanced non-small cell lung cancer.
[About TYK MEDICINES-B (02410)] TYK MEDICINES-B is an innovative biopharmaceutical company listed in Hong Kong, rooted in China and with a global vision. It focuses on the research, development, and commercialization of next-generation kinase inhibitors, targeting major unmet clinical needs in oncology. Since its establishment in 2017, the company has built a comprehensive innovative drug R&D system, with a pipeline of over ten differentiated innovative candidates spanning from preclinical to Phase III stages. Guided by its core mission of "developing more effective and safer anti-tumor drugs," the company consistently delivers high-quality clinical outcomes, dedicated to providing global cancer patients with high-quality, accessible innovative treatment solutions.
Comments